SUN-LB054 Cilengitide Reverts Thyroid Hormones Effects in Bexarotene Treatment of Breast Cancer Cells
| Autor: | Johanna Abigail Díaz Albuja, María Celeste Díaz Flaqué, Florencia Cayrol, Maria Mercedes Debernardi, Graciela Cremaschi, Cinthia Rosemblit |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Bexarotene
Tumor Biology: Translational Investigations of Endocrine Tumors and Cancer Therapies business.industry Endocrinology Diabetes and Metabolism Cilengitide chemistry.chemical_compound chemistry Thyroid hormones Cancer research Medicine Tumor Biology Breast cancer cells business medicine.drug |
| Zdroj: | Journal of the Endocrine Society |
| ISSN: | 2472-1972 |
| Popis: | Bexarotene (Bex) is an oral retinoid-X-receptor agonist that is effective for the treatment of early and advanced-stage in cutaneous T cell lymphoma. There are ongoing clinical trials to determine its role in both breast cancer treatment and prevention. Unfortunately, hypothyroidism is recognized as an important side effect of such therapy, potentially manageable by thyroid hormones (THs) co-administration. We previously found (1) that physiological levels of THs increased cell proliferation of different subtypes of human T cell lymphoma by activating both the nuclear (TR) and membrane (integrin αVβ3) THs receptors. We first demonstrated that MDA-MB-231 triple negative breast cancer cells expressed both TR and integrin αvβ3 dimer. Also, we found that THs induced MDA-MB-231 cell proliferation (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|